Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GF-CART01
- Development stage
- Phase 1
- Lead developer
- GenomeFrontier Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
GF-CART01 is a dual-targeting, safety switch-equipped chimeric antigen receptor (CAR) T cell therapy developed for the treatment of B cell malignancies. It is engineered to target both CD19 and CD20 antigens on malignant B cells, enhancing its efficacy against a range of B-cell hematological cancers. The therapy incorporates a genetic safety switch to allow controlled elimination of the CAR-T cells if needed, improving patient safety. GF-CART01 is manufactured using GenomeFrontier’s proprietary Quantum Engine™ platform, which utilizes virus-free gene modification technologies for efficient and robust CAR-T cell production with high proportions of stem cell memory T cells (TSCM), believed to be therapeutically advantageous. As of April 2025, GF-CART01 is in preclinical development with plans for Phase I clinical trials in patients with relapsed or refractory B-cell hematological malignancies who have failed at least two lines of standard therapies or autologous stem cell transplantation[1][2][4][5][6][8].
- Other names
- GF CART 01
02
Targets
Beyond the preview
Go deeper on GF-CART01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GF-CART01.